Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARS PharmaceuticalsSPRY +1.51%28 Receivables Turnover is 0.84 as of Mar. 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 843 Biotechnology companies, ARS Pharmaceuticals ranks worse than 64.65% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ARS Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $22.68 Mil. ARS Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $27.00 Mil.
Hence, ARS Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.84.
ARS Pharmaceuticals (NAS:SPRY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ARS Pharmaceuticals Receivables Turnover Related Terms
ARS Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRY vs ALLO, CBIO, IMMX: Receivables Turnover Comparison
For the Biotechnology subindustry, ARS Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (SPRY) has a Receivables Turnover of 0.84 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ARS Pharmaceuticals and its competitors. According to the industry distribution chart, ARS Pharmaceuticals ranks #545 out of 843 companies in the Biotechnology industry, placing it in the top 64.7%.
Is ARS Pharmaceuticals' Receivables Turnover too high?
ARS Pharmaceuticals' current Receivables Turnover is 0.84. The Biotechnology industry median Receivables Turnover is 5.27. ARS Pharmaceuticals' value of 0.84 is 84.1% below this industry median. Based on the distribution chart, ARS Pharmaceuticals ranks #545 out of 843 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' Receivables Turnover compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #545 out of 843 companies for Receivables Turnover. This places ARS Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.27. ARS Pharmaceuticals' value of 0.84 is 84.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ARS Pharmaceuticals's current Receivables Turnover of 0.84 is 84.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ARS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ARS Pharmaceuticals's current Receivables Turnover is 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current Receivables Turnover of 0.84. The current Receivables Turnover is 0.84 and 84.1% below the Biotechnology industry median of 5.27. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current Receivables Turnover is 0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score
Get the complete analysis for SPRY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
